PMID- 36836874
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230301
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 13
IP  - 2
DP  - 2023 Feb 13
TI  - Regulation of Liver Glucose and Lipid Metabolism by Transcriptional Factors and 
      Coactivators.
LID - 10.3390/life13020515 [doi]
LID - 515
AB  - The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide is on the 
      rise and NAFLD is becoming the most common cause of chronic liver disease. In the 
      USA, NAFLD affects over 30% of the population, with similar occurrence rates 
      reported from Europe and Asia. This is due to the global increase in obesity and 
      type 2 diabetes mellitus (T2DM) because patients with obesity and T2DM commonly 
      have NAFLD, and patients with NAFLD are often obese and have T2DM with insulin 
      resistance and dyslipidemia as well as hypertriglyceridemia. Excessive 
      accumulation of triglycerides is a hallmark of NAFLD and NAFLD is now recognized 
      as the liver disease component of metabolic syndrome. Liver glucose and lipid 
      metabolisms are intertwined and carbon flux can be used to generate glucose or 
      lipids; therefore, in this review we discuss the important transcription factors 
      and coactivators that regulate glucose and lipid metabolism.
FAU - Ramatchandirin, Balamurugan
AU  - Ramatchandirin B
AUID- ORCID: 0000-0003-0390-1878
AD  - Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, 
      MD 21287, USA.
FAU - Pearah, Alexia
AU  - Pearah A
AD  - Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, 
      MD 21287, USA.
FAU - He, Ling
AU  - He L
AD  - Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, 
      MD 21287, USA.
AD  - Department of Pharmacology and Molecular Sciences, Johns Hopkins University 
      School of Medicine, 600 N. Wolfe St, Baltimore, MD 21287, USA.
LA  - eng
GR  - R01 DK107641/DK/NIDDK NIH HHS/United States
GR  - R01 DK120309/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20230213
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC9962321
OTO - NOTNLM
OT  - fatty liver
OT  - obesity
OT  - type 2 diabetes
COIS- The authors declare no conflict of interest.
EDAT- 2023/02/26 06:00
MHDA- 2023/02/26 06:01
PMCR- 2023/02/13
CRDT- 2023/02/25 03:20
PHST- 2023/01/12 00:00 [received]
PHST- 2023/02/08 00:00 [revised]
PHST- 2023/02/10 00:00 [accepted]
PHST- 2023/02/25 03:20 [entrez]
PHST- 2023/02/26 06:00 [pubmed]
PHST- 2023/02/26 06:01 [medline]
PHST- 2023/02/13 00:00 [pmc-release]
AID - life13020515 [pii]
AID - life-13-00515 [pii]
AID - 10.3390/life13020515 [doi]
PST - epublish
SO  - Life (Basel). 2023 Feb 13;13(2):515. doi: 10.3390/life13020515.